Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amended AMNOG Sees New Life Breathed Into Trajenta Reimbursement Bid In Germany

This article was originally published in The Pink Sheet Daily

Executive Summary

Changes to Germany’s drug reimbursement law have permitted Boehringer Ingelheim and Eli Lilly to submit an updated dossier for their oral therapy Trajenta, giving medicine makers who operate there hope that further positive amendments will occur.

You may also be interested in...

Germany’s IQWiG Fells AstraZeneca’s Caprelsa Again, Proving Mortality Trumps All

AstraZeneca’s Caprelsa has failed to take advantage of a second assessment chance at IQWiG, and it seems clear the company and the assessor never saw eye-to-eye on trial design.

Bayer’s Eylea Shot Down By IQWiG On A Technicality

Germany’s IQWiG has tightened the screw on reimbursement submissions, rejecting Bayer’s Eylea for AMD on technical grounds concerning its comparator.

German Pricing Plan Avoids Terrible Twos, But More Growing Pains Ahead

In the two years since Germany’s reimbursement process for new drugs turned Europe’s largest market into one of the toughest, the impact on pricing hasn’t been as bad as many expected. But there’s more to come, with several on-market categories slated for retrospective review, and even mandatory rebates could follow.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts